Fluoroquinolones and anaerobes

被引：54

作者：

Stein, GE

Goldstein, EJC

机构：

[1] Michigan State Univ, Dept Med, E Lansing, MI 48824 USA

[2] Michigan State Univ, Dept Pharmacol, E Lansing, MI 48824 USA

[3] Univ Calif Los Angeles, Sch Med, Dept Med, Los Angeles, CA 90024 USA

[4] RM Alden Res Lab, Santa Monica, CA USA

来源：

CLINICAL INFECTIOUS DISEASES | 2006年 / 42卷 / 11期

关键词：

D O I：

10.1086/503907

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The usefulness of fluoroquinolones for the treatment of mixed aerobic and anaerobic infections has been investigated since these agents started being used in clinical practice. Newer compounds have increased in vitro activity against anaerobes, but clinically relevant susceptibility breakpoints for these bacteria have not been established. Pharmacodynamic analyses and corroboration by new data from clinical trials have enhanced our knowledge concerning the use of fluoroquinolones to treat selective anaerobic pathogens. These studies suggest that newer agents could be useful in the treatment of several types of mixed aerobic and anaerobic infections, including skin and soft-tissue, intra-abdominal, and respiratory infections. The major concerns with expanding the use of fluoroquinolones to treat anaerobic infections have been reports of increasing resistance in Bacteroides group isolates and the impact of these antibiotics on the incidence of Clostridium difficile-associated disease.

引用

收藏

页码：1598 / 1607

页数：10

相关论文

共 106 条

[1] Resistance to moxifloxacin in toxigenic Clostridium difficile isolates is associated with mutations in gyrA [J].

Ackermann, G ;

Tang, YJ ;

Kueper, R ;

Heisig, P ;

Rodloff, AC ;

Silva, J ;

Cohen, SH .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (08) :2348-2353

[2] Bacteremia due to Bacteroides fragilis group:: distribution of species, β-lactamase production, and antimicrobial susceptibility patterns [J].

Aldridge, KE ;

Ashcraft, D ;

O'Brien, M ;

Sanders, CV .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (01) :148-153

[3] Comparison of the in vitro activities of Bay 12-8039, a new quinolone, and other antimicrobials against clinically important anaerobes [J].

Aldridge, KE ;

Ashcraft, DS .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (03) :709-711

[4] Clinical pharmacodynamics of quinolones [J].

Ambrose, PG ;

Bhavnani, SM ;

Owens, RC .

INFECTIOUS DISEASE CLINICS OF NORTH AMERICA, 2003, 17 (03) :529-+

[5] Anaerobic activity of levofloxacin and metronidazole separately and in combination [J].

Barry, AL ;

Brown, SD .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1996, 37 (06) :1178-1179

[6] Changing patterns of fluoroquinolone resistance among Bacteroides fragilis group organisms over a 6-year period (1997-2002) [J].

Betriu, C ;

Rodríguez-Avial, I ;

Gómez, M ;

Culebras, E ;

Picazo, JJ .

DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2005, 53 (03) :221-223

[7] PHARMACOKINETICS AND SERUM BACTERICIDAL ACTIVITIES OF QUINOLONES IN COMBINATION WITH CLINDAMYCIN, METRONIDAZOLE, AND ORNIDAZOLE [J].

BOECKH, M ;

LODE, H ;

DEPPERMANN, KM ;

GRINEISEN, S ;

SHOKRY, F ;

HELD, R ;

WERNICKE, K ;

KOEPPE, P ;

WAGNER, J ;

KRASEMANN, C ;

BORNER, K .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1990, 34 (12) :2407-2414

[8] Bactericidal activity of trovafloxacin under anaerobic and aerobic conditions [J].

Boswell, FJ ;

Andrews, JM ;

Wise, R .

INFECTIOUS DISEASES IN CLINICAL PRACTICE, 1996, 5 :S113-S116

[9] INVIVO EFFICACIES OF QUINOLONES AND CLINDAMYCIN FOR TREATMENT OF INFECTIONS WITH BACTEROIDES-FRAGILIS AND OR ESCHERICHIA-COLI IN MICE - CORRELATION WITH INVITRO SUSCEPTIBILITIES [J].

BROOK, I .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1993, 37 (05) :997-1000

[10] Comparative in vitro activities of trovafloxacin (CP-99,219) against 221 aerobic and 217 anaerobic bacteria isolated from patients with intra-abdominal infections [J].

Citron, DM ;

Appleman, MD .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1997, 41 (10) :2312-2316

← 1 2 3 4 5 6 7 8 9 10 →